PURPOSE: In prostate seed brachytherapy, a D90 of <130  Gy is an accepted predictive factor for @entity177 ( @entity177 ). We studied whether there is a subpopulation that does not need additional treatment after a suboptimal permanent seed brachytherapy implantation. METHODS AND MATERIALS: A total of 486 @entity1 who had either @entity177 or a minimum followup of 48  months without @entity177 were identified. @entity177 was defined according to the Phoenix definition (nadir @entity1486  +  2). Univariate and multivariate analyses were performed, adjusting for known prognostic factors such as D90 and @entity1486 density (PSAD) of >= 0.15  ng/mL/cm(3), to evaluate their ability to predict @entity177 . RESULTS: Median followup for @entity1 without @entity177 was 72  months (interquartile range 56-96). @entity177 -free recurrence rate at 5  years was 95% and at 8  years 88%. In univariate analysis, PSAD and @entity5 of the prostate risk assessment score were predictive of @entity177 . On multivariate analysis, none of the factors remained significant. The best prognosis had @entity1 with a low PSAD (<0.15  ng/mL/cm(3)) and an optimal implant at 30  days after implantation (as defined by D90  >=   130  Gy) compared to @entity1 with both factors unfavorable (p  = 0.006). A favorable PSAD was associate with a good prognosis, independently of the D90 (<130  Gy vs. >= 130  Gy, p  = 0.7). CONCLUSIONS: @entity1 with a PSAD of <0.15  ng/mL/cm(3) have little risk of @entity177 , even in the case of a suboptimal implant. These results need to be validated in other @entity1 ' cohorts.

XXXX density is predictive of outcome in suboptimal prostate seed brachytherapy.

@entity177 :: ('MESH:D051437', 'Disease') :: ['BF', 'biochemical failure'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity1486 :: (354,Gene) :: ['Prostate-specific antigen']
